close 76% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 76% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Dashboard

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Strona główna・Stock List・Nektar Therapeutics
Search

Nektar Therapeutics

Closed

22.78 5.95

Buy

Price update 1 sie 2025, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

20.8

Max

22.97

Key metrics

By Trading Economics

Income

-58M

-51M

Sales

-19M

10M

Profit margin

-486.444

Employees

61

EBITDA

-58M

-41M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+334.07% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

409M

Previous open

16.83

Previous close

22.78

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5949 / 0.7406 Support & Resistance

Nektar Therapeutics Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 lip 2025, 23:56 UTC

Hot Stocks

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

DJ

Read

31 lip 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

DJ

Read

31 lip 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

DJ

Read

31 lip 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

DJ

Read

31 lip 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

DJ

Read

31 lip 2025, 23:12 UTC

Earnings

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

DJ

Read

31 lip 2025, 23:10 UTC

Earnings

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

DJ

Read

31 lip 2025, 23:09 UTC

Earnings

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

DJ

Read

31 lip 2025, 23:08 UTC

Earnings

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

DJ

Read

31 lip 2025, 23:08 UTC

Earnings

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

DJ

Read

31 lip 2025, 23:01 UTC

Earnings

Amazon Posts Higher Sales, Profit -- 3rd Update

DJ

Read

31 lip 2025, 22:08 UTC

Market Talk
Earnings

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

DJ

Read

31 lip 2025, 22:02 UTC

Market Talk
Earnings

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

DJ

Read

31 lip 2025, 21:57 UTC

Market Talk
Earnings

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

DJ

Read

31 lip 2025, 21:50 UTC

Earnings

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

DJ

Read

31 lip 2025, 21:43 UTC

Earnings

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

DJ

Read

31 lip 2025, 21:29 UTC

Earnings

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

DJ

Read

31 lip 2025, 21:26 UTC

Earnings

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

DJ

Read

31 lip 2025, 21:26 UTC

Earnings

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

DJ

Read

31 lip 2025, 21:22 UTC

Earnings

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

DJ

Read

31 lip 2025, 21:19 UTC

Earnings

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

DJ

Read

31 lip 2025, 21:19 UTC

Earnings

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

DJ

Read

31 lip 2025, 21:14 UTC

Earnings

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

DJ

Read

31 lip 2025, 21:12 UTC

Earnings

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

DJ

Read

31 lip 2025, 21:10 UTC

Earnings

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

DJ

Read

31 lip 2025, 21:09 UTC

Earnings

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

DJ

Read

31 lip 2025, 21:09 UTC

Earnings

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

DJ

Read

31 lip 2025, 21:08 UTC

Earnings

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

DJ

Read

31 lip 2025, 21:08 UTC

Earnings

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

DJ

Read

31 lip 2025, 21:05 UTC

Earnings

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

DJ

Read

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

334.07% upside

12 Months Forecast

Average 95.8 USD  334.07%

High 120 USD

Low 69 USD

Based on 7 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

5

Buy

1

Hold

1

Sell

Based on 7 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

0.5949 / 0.7406Support & Resistance

Short Term

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

JNJ

Johnson and Johnson

167.25

↑ +1.51%

NVS

Novartis AG

115.07

↑ +1.29%

ABT

Abbott Laboratories

127.38

↑ +0.96%

TMO

Thermo Fisher Scientific Inc

462.78

↓-1.04%

ISRG

Intuitive Surgical Inc

483.28

↑ +0.46%